Mater Private Network has been selected as one of only three centres worldwide and the only centre in Ireland to participate in the prestigious NAVIGATE-PF clinical study, led by Boston Scientific. This recognition highlights Mater Private Network’s status as one of the most acknowledged atrial fibrillation (AFib) centres in Europe.
The prospective, single-arm, open-label, multi-centre NAVIGATE-PF study will begin at the Dublin site from today, Friday 10th May, marking a significant step in Mater Private Network’s involvement in pioneering medical research. AFib is the most common irregular heart rhythm, which significantly reduces the quality of life and life expectancy of patients. An estimated 8 million patients live with this condition in Europe.
For verified healthcare professionals
Log in or register for free to read this article. HPN is for healthcare professionals, so new accounts are verified by our team.
